A leading global contract development and manufacturing organization – CDMO for biopharmaceuticals, Rentschler Biopharma, and Coriolis Pharma, which is a globally operating contract research and development organization – CRDO and also a leader in formulation research and development when it comes to biopharmaceuticals, announced on December 02, 2025, a strategic collaboration.
Together, the companies are going to offer clients seamless as well as end-to-end solutions right from early formulation to commercial manufacturing, therefore combining their complementary expertise in order to speed up the path to market of the product. This collaboration goes on to respond to the evolving requirements of the biologics market, as the growing complexity in modalities as well as regulatory expectations go on to drive the demand when it comes to integrated and science-driven solutions. Clients are surely going to benefit from a unified interface along with aligned project teams, decreasing the tech transfer risks and also helping with a much faster progression right from an early development to clinical as well as commercial stages.
To cater to the requirements of the biologics market, Coriolis Pharma goes on to bring a very distinct combination of in silico as well as wet lab formulation and also drug product development expertise, scientific depth along with advanced analytical ability to this collaboration. Due to a legacy of scientific excellence along with the commitment to innovation, Coriolis goes on to support every drug development phase, be it R&D or GMP. The collaborative approach, along with the deep scientific expertise of the company, makes them a dependable partner from discovery to commercial manufacturing as well as lifecycle management.
On the other hand, Rentschler Biopharma brings quite an extensive experience within the bioprocess development and manufacturing for multiple biotherapeutics that are backed by a robust track record of dependability as well as quality. Because of a long-standing commitment to client-centric solutions, Rentschler Biopharma offers very strong support from process development to commercial supply. Through focusing on technical excellence, long-term partnerships as well as customised solutions, Rentschler Biopharma makes sure of successful outcomes across each and every stage of the project.
According to the Chief Executive Officer of Coriolis Pharma, Silvia Steyrer-Gruber, at Coriolis, they believe that scientific excellence, client-focused innovation along with robust partnerships are indeed key to advancing the intricate biopharmaceutical programs in an efficient and reliable way. With Rentschler Biopharma, they have a dependable partner whose process development as well as manufacturing expertise ideally complements their deep understanding when it comes to formulation development as well as analytical services. This collaboration is indeed a testament to their Coriolis partnering strategy, which makes use of synergistic relationships throughout the biopharma ecosystem. Together, they can indeed offer clients connected and science-driven solutions that help them move their projects towards success. She added that their teams look forward to working closely along with Rentschler Biopharma on this collab. Apparently, the integrated service offering is going to be available to clients from December 2025. Both the organizations have operations across Germany and the United States, which in a way offer global reach as well as local access for clients in major biopharmaceutical markets.
